Zetia Name Accepted Based On Sponsor Data, Despite DMETS Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck/Schering-Plough’s market analysis of the Zetia tradename was sufficient to alleviate FDA’s concerns about name confusion, NDA review documents indicate.
You may also be interested in...
Merck/Schering Zetia Effects On Triglycerides, HDL-C Questioned In Review
FDA and Merck/Schering-Plough reached a middle ground on Zetia’s indication, allowing the “small” and “variable” effects on triglycerides and HDL-cholesterol to be described in the clinical studies section of labeling, but not permitting inclusion in the indications section, FDA review documents show.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product